Animal Models of Hemophilia
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The X-linked bleeding disorder hemophilia is caused by mutations in coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Unless prophylactic treatment is provided, patients with severe disease (less than 1% clotting activity) typically experience frequent spontaneous bleeds. Current treatment is largely based on intravenous infusion of recombinant or plasma-derived coagulation factor concentrate. More effective factor products are being developed. Moreover, gene therapies for sustained correction of hemophilia are showing much promise in pre-clinical studies and in clinical trials. These advances in molecular medicine heavily depend on availability of well-characterized small and large animal models of hemophilia, primarily hemophilia mice and dogs. Experiments in these animals represent important early and intermediate steps of translational research aimed at development of better and safer treatments for hemophilia, such a protein and gene therapies or immune tolerance protocols. While murine models are excellent for studies of large groups of animals using genetically defined strains, canine models are important for testing scale-up and for longer-term follow-up as well as for studies that require larger blood volumes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 3×
“Clinically, this correlates with findings that hemophilia A pediatric patients that receive regular recombinant FVIII (rFVIII) treatments are 83% less likely to develop bone and cartilage changes compared to episodic treatments for bleeding.(42) Using these mouse models to measure the impact of bleeding on the joint i…”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 1×
“While AAV is nonpathogenic and is not associated with the pathology of adenoviral infections, the human population has been exposed to wild-type AAV infections that establish immunity to these viruses that impacts the transduction and long-term expression using these vectors.(104) These hurdles must be overcome for tr…”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 3×
“Unfortunately, this conclusion also cannot be tested in the hemophilia B mouse.(248) Other groups responded to the clinical trial results by returning to the hemophilia B mice to examine and optimize AAV vector design and to address the hypothesis that more highly efficient FIX vectors might direct hepatic FIX express…”
BackgroundResultInfluentialSelf-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“In 2001, novel AAV vectors were reported that incorporated a ‘‘self-complementary’’ genomic form (scAAV) that bypasses the rate-limiting requirement for DNA secondstrand synthesis prior to expression and could be used to deliver therapeutic transgenes.(249) Optimization of elements for incorporation in a FIX expressio…”
BackgroundSelf-citationAAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 1×
“These observations are particularly important when considering the occurrence of hepatocellular carcinoma and angiosarcomas in mice with the lysosomal storage disease mucopolysaccharidosis type VII (MPSVII) after treatment with rAAV vectors.(309,310) Insertional mutagenesis is probably the operative mechanism but othe…”
BackgroundIn vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548 · cited 1×
“(4) Further develop the recent approach of targeted integration for safe and persistent gene therapy.(259)”
BackgroundInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 3×
“…exon 17 knockout Reipert et al. 2009 Mouse Hemophilia B Targeted deletion Lin et al. 1997 • C57BL6 Mingozzi et al. 2003 • BALB/c Mingozzi et al. 2003 • C3H/HeJ Mingozzi et al. 2003 Hemophilia B Knock-in for human F.IX with crm+ missense mutation R333Q Jin et al. 2004 Hemophilia B Knock-in for…”
BackgroundInfluentialSelf-citationNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345 · cited 2×
“Preclinical studies of a self-complementary AAV serotype 8 codon-optimized FIX vector (scAAV8FIXco) in hemophilia B mice and hemostatically normal primates led to a human clinical trial sponsored by St Jude Children’s Research Hospital and conducted at the University College London.(252) In 2010, the first report of s…”
Method
Cited by
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Evolutionary Insights Into Coagulation Factor IX Padua and Other High-Specific-Activity Variants
Samelson-Jones, B. J., Finn, J. D., Raffini, L. J., Merricks, E. P., Camire, R. M., Nichols, T. C., & Arruda, V. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2019000405 · Cited by 31
Self-citationThe immune response to the fVIII gene therapy in preclinical models
Patel, S. R., Lundgren, T. S., Spencer, H. T., & Doering, C. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00494 · Cited by 29
Metadata
- Authors
- Sabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., & Monahan, P. E.
- Venue
- Progress in Molecular Biology and Translational Science
- Publisher
- Elsevier
- Published
- 2012
- Volume
- 105
- Pages
- 151-209
- ISSN
- 1877-1173 (ISSN-L)
- OpenAlex
- W1587977041
- Cited by
- 66
- References
- 30
- FWCI
- 16.55
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Animal Models of Hemophilia. https://app.cochat.ai/papers/10.1016/b978-0-12-394596-9.00006-8
- The paper
- Sabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., & Monahan, P. E. (2012). Animal Models of Hemophilia. Progress in Molecular Biology and Translational Science. https://doi.org/10.1016/b978-0-12-394596-9.00006-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.